We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+25.69%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$2.85B
AUM Growth
+$604M
Cap. Flow
+$513M
Cap. Flow %
18.04%
Top 10 Hldgs %
65.03%
Holding
69
New
10
Increased
6
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$320M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$126M
3
TERN
Terns Pharmaceuticals
TERN
+$58.6M
4
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$35.9M
5
DSGN icon
Design Therapeutics
DSGN
+$17.9M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$20.3M
2
ZGNX
Zogenix, Inc.
ZGNX
+$18.5M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$17M
4
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$10.2M
5
MTNB icon
Matinas BioPharma
MTNB
+$8.77M

Sector Composition

Rank Sector Weight
1 Healthcare 85.49%
2 Materials 8.84%
3 Financials 5.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
51
Syndax Pharmaceuticals
SNDX
$1.76B
$7.16M 0.25%
+320,000
New +$7.23M
AUPH icon
52
Aurinia Pharmaceuticals
AUPH
$2.07B
$6.5M 0.23%
500,732
– –
KALA icon
53
KALA BIO
KALA
$14.2M
$5.3M 0.19%
315
– –
ATRC icon
54
AtriCure
ATRC
$2.01B
$4.23M 0.15%
64,573
– –
MRUS
55
DELISTED
Merus
MRUS
$3.66M 0.13%
+175,000
New +$4.04M
CNST
56
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$3.28M 0.12%
140,298
– –
TXG icon
57
10x Genomics
TXG
$5.79B
$2.68M 0.09%
14,798
-44,179
-75% -$7.63M
ZGNX
58
DELISTED
Zogenix, Inc.
ZGNX
$2.05M 0.07%
105,000
-901,494
-90% -$18.5M
YARW
59
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
$1.61M 0.06%
261
– –
IGMS
60
DELISTED
IGM Biosciences
IGMS
$1.53M 0.05%
20,000
– –
DTIL icon
61
Precision BioSciences
DTIL
$191M
$1.45M 0.05%
4,675
– –
TCDA
62
DELISTED
Tricida, Inc. Common Stock
TCDA
$924K 0.03%
174,763
– –
MTCR
63
DELISTED
Metacrine, Inc. Common Stock
MTCR
$908K 0.03%
146,426
– –
MTNB icon
64
Matinas BioPharma
MTNB
$1.72M
– –
-129,032
Closed -$8.77M
OVID icon
65
Ovid Therapeutics
OVID
$495M
– –
-1,250,000
Closed -$2.89M
RCKT icon
66
Rocket Pharmaceuticals
RCKT
$387M
– –
-310,584
Closed -$17M
RVMD icon
67
Revolution Medicines
RVMD
$42.1B
– –
-16,690
Closed -$661K
PSTX
68
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
– –
-926,447
Closed -$10.2M
CBAY
69
DELISTED
Cymabay Therapeutics
CBAY
– –
-585,394
Closed -$3.36M
1 2
3

Similar funds

FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM
CCM
Condor Capital Management Martinsville, New Jersey $1.2B AUM 13.18% 1-Year Est. Return
TIM
Tortoise Investment Management White Plains, New York $1.21B AUM 13.04% 1-Year Est. Return
CS
Central Securities New York $1.21B AUM 19.91% 1-Year Est. Return
KOC
Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Vivo Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Vivo Capital held 69 positions worth $2.85B, up 27% from $2.24B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Vivo Capital deployed $513M of net new capital in Q1 2021, opening 10 new positions and adding to 6 existing holdings. Its largest new stake was Instil Bio: 624,339 shares worth $313M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 91% a quarter earlier, followed by Materials and Financials.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $20.3M trimmed.

  • Vivo Capital's largest Q1 2021 buy was Instil Bio: 624,339 shares worth $313M.
  • Vivo Capital added most to KalVista Pharmaceuticals in Q1 2021, an estimated $6.44M increase.
  • Vivo Capital's biggest Q1 2021 reduction was Ascendis Pharma A/S, cutting an estimated $20.3M.
  • Vivo Capital fully exited Rocket Pharmaceuticals in Q1 2021, selling an estimated $17M.
  • Vivo Capital's ten largest holdings make up 65% of its $2.85B portfolio in Q1 2021.
  • Vivo Capital opened 10 new positions and closed 6 in Q1 2021.
  • Vivo Capital's portfolio value rose 27% quarter-over-quarter to $2.85B.

Based on Vivo Capital's 13F filing for Q1 2021, filed 17 May 2021.